NOTCH3 Blockade Inhibits Cancer Cell Plasticity through a NOTCH3/PD-L1 Oncogenic Axis in Triple Negative Breast Cancer
RNA-seq (gene expression) · human · 27 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Breast cancerThis series is part of our curated briefing on it.
- Samples
- 27 samples: 27 × P25801Groups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE236140_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA989131 and SRA study SRP446931. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 27 samples.
How we read this: 1 replicated groups read from 27 sample titles; they account for 27 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7518764 P25801_101 P25801
- GSM7518765 P25801_102 P25801
- GSM7518766 P25801_103 P25801
- GSM7518767 P25801_104 P25801
- GSM7518768 P25801_105 P25801
- GSM7518769 P25801_106 P25801
- GSM7518770 P25801_113 P25801
- GSM7518771 P25801_114 P25801
- GSM7518772 P25801_115 P25801
- GSM7518773 P25801_116 P25801
- GSM7518774 P25801_117 P25801
- GSM7518775 P25801_118 P25801
- GSM7518776 P25801_107 P25801
- GSM7518777 P25801_108 P25801
- GSM7518778 P25801_109 P25801
- GSM7518779 P25801_110 P25801
- GSM7518780 P25801_111 P25801
- GSM7518781 P25801_112 P25801
- GSM7518782 P25801_119 P25801
- GSM7518783 P25801_120 P25801
- GSM7518784 P25801_121 P25801
- GSM7518785 P25801_122 P25801
- GSM7518786 P25801_123 P25801
- GSM7518787 P25801_124 P25801
- GSM7518788 P25801_125 P25801
- GSM7518789 P25801_126 P25801
- GSM7518790 P25801_127 P25801
- GSE11121 The humoral immune system has a key prognostic impact in node-negative breast cancer 200 samples same disease briefing · shares negative
- GSE104193 Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signalling and malignant features in vitro and in vivo 32 samples same disease briefing
- GSE104675 Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 6 samples same disease briefing
- GSE10885 An integromic analysis reveals that metaplastic carcinomas are distinct from basal-like tumors. 244 samples same disease briefing
- GSE10886 A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes 226 samples same disease briefing
- GSE169246 PD-L1 blockade-induced temporal single cell dynamics in triple negative breast cancer 83 samples shares pd-l1, blockade, negative, triple
- GSE279750 ACE2 Enhances Sensitivity to PD-L1 Blockade by Inhibiting Macrophage-Induced Immunosuppression and Angiogenesis [RNA-seq, anti-PD-L1 therapy] 10 samples shares pd-l1, blockade
- GSE325770 Concurrent CDK7 and CDK9 Blockade Sustains Transcriptional Shutdown and Suppresses Oncogenic Dependencies in Cancer 33 samples shares oncogenic, blockade
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.